Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –
Vaxart revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Vaxart's revenue for the twelve months ending Jun 30, 2026 was $243.06M, up 201.1% year over year. For fiscal 2025 it was $237.26M, up 726.7% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $237.26M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.26M | +726.7% |
| FY2024 | Dec 31, 2024 | $28.70M | +288.9% |
| FY2023 | Dec 31, 2023 | $7.38M | +6796.3% |
| FY2022 | Dec 31, 2022 | $107.00K | -88.0% |
| FY2021 | Dec 31, 2021 | $892.00K | -78.0% |
| FY2020 | Dec 31, 2020 | $4.05M | -59.0% |
| FY2019 | Dec 31, 2019 | $9.86M | +137.1% |
| FY2018 | Dec 31, 2018 | $4.16M | -55.3% |
| FY2016 | Jun 30, 2016 | $9.30M | -62.2% |
| FY2015 | Jun 30, 2015 | $24.60M | -64.2% |
| FY2014 | Jun 30, 2014 | $68.70M | +104.5% |
| FY2013 | Jun 30, 2013 | $33.60M | +64.7% |
| FY2012 | Jun 30, 2012 | $20.40M | +94.5% |
| FY2009 | Dec 26, 2009 | $10.49M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $27.19M | -31.6% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $39.23M | +87.9% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $104.24M | +586.5% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $72.41M | +1367.9% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $39.73M | +520.7% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $20.88M | +857.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $15.19M | +368.0% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $4.93M | +134.8% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $6.40M | +371.4% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $2.18M | +223.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $3.25M | +14650.0% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $2.10M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $1.36M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $675.00K | +694.1% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $22.00K | -70.3% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $0 | -100.0% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $85.00K | -83.2% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $74.00K | -79.2% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $200.00K | -24.5% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $112.00K | -78.6% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $506.00K | -82.6% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $356.00K | -90.9% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $265.00K | -41.6% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $523.00K | +515.3% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $2.90M | -46.3% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $3.92M | +121.6% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $454.00K | +61.6% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $85.00K | -86.0% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $5.41M | +259.7% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $1.77M | +194.5% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $281.00K | -94.7% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $608.00K | -64.2% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $1.50M | -11.6% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $600.00K | -85.4% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $5.30M | -10.2% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $1.70M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $1.70M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $4.10M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $5.90M | – |
See a number that looks wrong?